~~<i id='A39CBBECAB'><strike id='A39CBBECAB'><tt id='A39CBBECAB'><pre id='A39CBBECAB'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：explore 2025-09-06 01:34:49 Page View：4693

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage
Next article： Medicare details structure of new drug price negotiation program

focus

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

FDA warns medical device makers about rise in fabricated data

ManuelBalceCeneta/APAnincreasingnumberofmedicaldevicecompaniesaresubmittingfabricatedandunreliableda

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

3:16SingersTonyBennettandBillyJoelperformtogetheronSept.22,2006,inNewYorkCity.BradBarket/GettyImages